Clario (formerly ERT + Bioclinica) eCOA alternatives for 2026
Clario is unmatched for cardiac safety, medical imaging, and specialised respiratory endpoints. If you came looking for eCOA and those aren't your endpoints, you're paying for infrastructure you don't need. WeGuide gives you validated eCOA, eConsent, wearables, and a whitelabel participant app on one regulatory-grade platform, priced for the study you're actually running.
No pressure, no hard sell. A 30-minute walkthrough with a research colleague who's built platforms like yours.
.png)
Used by leading research and medical institutes.
%201.avif)
Why research teams look for a Clario alternative
Clario's product and commercial model are built around one thing: running specialised endpoint capture at pharma scale. Provisioned iPads and smartphones shipped to sites, validated devices for cardiac safety and spirometry, and an enterprise operational layer that manages all of it. For a Phase III cardiovascular safety study, that's exactly what you need.
For teams that come to Clario through the eCOA door rather than the cardiac safety door, the conversation lands differently. Sponsors evaluating eCOA vendors often add Clario to their shortlist because of its eCOA category leadership, then discover the pricing reflects the full enterprise device logistics operation even if their study is a straightforward patient reported outcomes trial that could run BYOD on participants' own phones.
The other thing sponsors notice is product scope. Clario is deep in eCOA and specialised endpoints and intentionally narrow outside that. No patient registries. No employee wellbeing or population health programmes. No integrated telehealth. No whitelabel participant app built for engagement rather than endpoint capture. For studies that need eCOA as one ingredient in a broader patient engagement platform, Clario's specialisation becomes the constraint.
WeGuide takes a different approach. We're a patient engagement platform with eCOA built in, not an eCOA specialist with engagement bolted on. The two models serve different studies, and on this page we'll tell you honestly which is which.
%20(1).png)
Key differences between WeGuide and Clario
For teams evaluating Clario for eCOA where specialised endpoints aren't required, here's what changes when you move to WeGuide.
.png)
Whitelabel participant mobile apps
.png)
BYOD first architecture
.png)
Patient engagement, not just endpoint capture
Full comparison: WeGuide vs Clario
.png)
Top alternatives to Clario in 2026
Here's the shortlist of platforms most teams evaluate when they're looking at Clario for eCOA, or when Clario's pricing and provisioned-device model don't fit.
.png){kind=small}
.png){kind=small}
All-in-one platform
WeGuide combines eCOA, eConsent, data collection, and telehealth in a single platform with whitelabel apps under your own brand.
.png){kind=icon}
eConsent
.png)
.png){kind=icon}
Screening
.svg)
.svg)
.png){kind=icon}
Data collection
.svg)
.png){kind=icon}
Telehealth
.png)
.png)
.png)
%20(1)%20(1)%20(1).png)
%20(1).png)
.png)
.png)
Continuous engagement, not once-off surveys
Push notifications, educational content delivery, gamification, and a study companion that guides participants through the protocol. This is the difference between collecting data when a participant remembers and collecting data on schedule because the app is genuinely useful to them. The BRACE Trial achieved 90% adherence across 6,000 participants in five countries using this architecture. See WeGuide’s patient education module →
Push notifications and reminders
Study companion
Educational content and gamification
Mobile multimodal collection
Capture the full picture of a participant's experience through forms, video, pathology, and passive sensor data all in the same app.
Forms
.svg){kind=icon}
Video
.svg){kind=icon}
Pathology
.svg){kind=icon}
Sensors
.png)
%20(1).png)
.png)
%20(1).png)
.png)
%20(1).png)
.png)
Whitelabel: your study, your brand
WeGuide ships native iOS and Android apps fully branded under your organisation's name and identity. The app becomes the study's home for the participant, which is a big part of why our studies average 94% adherence.
.svg){kind=icon}
Your brand end-to-end
.svg){kind=icon}
App store distribution
.svg){kind=icon}
Multilingual out of the box.
Where WeGuide goes further
For teams that need the clinical layer without the rest of the Vault platform, here's what changes when you move from Veeva Clinical to WeGuide.
.svg)
Patient engagement, not just endpoint capture
.svg)
Whitelabel mobile apps under your brand
.svg)
BYOD-first architecture
.png)
Built in patient registry capability
Employee wellbeing, population health, and citizen science
No code programme builder for non-pharma research teams
Integrated eConsent, telehealth, and analytics
Accessible pricing for mid market research
Built for regulated research
Every WeGuide study runs on our managed infrastructure. Your IT team doesn't patch servers, manage backups, or run disaster recovery drills.
.png){kind=small}
TGA Certified
.png){kind=small}
ISO 27001
.png){kind=small}
Data Hosted in Australia
.png){kind=small}
GDPR Compliant
Biometric Security
.png){kind=small}
256-bit AES Encryption
Faster
Your own platform ready in weeks and changes are made in minutes
Adherence Rates
High patient engagement and better quality data
Cost Saving
Reduce financial and technology risk when creating a secure health app
Patients Impacted
With our ease of use and roll out, our apps have engaged 200k+ users
Where Clario genuinely excels
Deepest eCOA specialisation in the market. The ERT and Bioclinica merger created the clear category leader in eCOA for pharma trials. Twenty years of validated instruments, FDA submission precedents, and clinical endpoint experience sits in Clario's platform. For sponsors whose primary question is "which vendor has the deepest eCOA track record", the honest answer is Clario.
Cardiac safety endpoints. ECG, Holter, and 12-lead cardiac monitoring run on Clario's infrastructure at global scale. If your protocol requires centralised cardiac safety reads for a pharma study, Clario is the specialised choice and there's no direct mid-market substitute. WeGuide does not offer cardiac safety capabilities. If you need them, Clario or a specialist cardiac core lab is where you should be looking.
Medical imaging endpoints. Central image reading, real-time imaging quality control, and radiology workflow for oncology, cardiovascular, and neurology trials. Again, this is Clario territory, and WeGuide does not replace it.
Respiratory spirometry and precision motion. Validated respiratory endpoint capture and accelerometry-based motion analysis for neurology, movement disorders, and pulmonology trials. Specialised capabilities that come from decades of Bioclinica and ERT investment in sensor science.
Provisioned device logistics at global scale. Clario ships and manages thousands of validated devices per trial. For protocols where the device itself is part of the regulatory evidence chain, the provisioned model is a genuine advantage. WeGuide's BYOD-first architecture is a different philosophy and not a direct substitute in studies that require provisioned device control.
20+ years of FDA submission history. Regulatory precedent matters. Clario-sourced eCOA data has been accepted in FDA submissions across hundreds of studies. That track record is an asset that newer platforms have to earn.
Topical authority in eCOA. Clario ranks #1 in Google for "ecoa clinical trials" for a reason. The company invests heavily in educational content, and the eCOA category leadership is reflected in both product and thought leadership.
If your study needs cardiac safety, medical imaging, respiratory endpoints, or specialised motion analysis, Clario is the right tool. We'd rather say that honestly and help you make the right decision than try to pitch WeGuide into a study where it doesn't belong.
WeGuide and Clario can coexist
For studies that need both patient engagement and specialised Clario endpoints, the two platforms can run together. Our Integration Engine connects to Clario through APIs, so Clario handles cardiac safety, imaging, or respiratory endpoint capture while WeGuide runs the broader participant experience, eCOA, eConsent, and engagement layer. Hybrid architectures are common with teams who need both.
How the switch works
For teams that are evaluating Clario for eCOA and considering WeGuide instead, or for teams that want to run both, here's how onboarding typically plays out.
Discovery Call
A 30-minute conversation with one of our research delivery team. We look at your protocol, your eCOA requirements, and which platform is actually the right fit. If your study needs cardiac safety or imaging, we'll tell you Clario is the right choice.
Study Configuration
Our team works alongside yours to configure the study in WeGuide. Typical timeline: two to four weeks.
.svg)
Participant Onboarding
The whitelabel app goes live. Your research coordinators invite participants, who download the app under your organisation's brand. eCOA instruments, consent flows, and engagement templates are ready.
Ongoing Support
You get a named research delivery contact, not a ticketing queue. We stay involved for the life of the study.
.png)
.png)
.png)
.png)
Case studies: research teams that needed engagement led eCOA
BRACE Trial (Murdoch Children's Research Institute)
A global randomised controlled trial studying whether the BCG vaccine could reduce COVID-19 symptom severity. Launched across five countries with 6,000+ participants in six weeks during the pandemic. Adherence exceeded 90%. eCOA instruments ran inside the BRACE whitelabel app alongside engagement content, not as a separate endpoint capture module.
GenV (Generation Victoria)
A population health registry tracking more than 100,000 Victorian families from birth. Longitudinal eCOA at registry scale, delivered through a family-facing whitelabel app that participants keep on their phones for years. Registry territory that sits entirely outside Clario's scope.
INHERIT
A multilingual COVID-19 study supporting diverse community populations. Dynamic translation management and culturally adapted eCOA content delivered through the participant app. The kind of community health eCOA work where engagement is the whole job.
%201.avif)
Questions
Straight answers on how WeGuide compares to Clario, what integration looks like, and when Clario is the right choice.
Contact usIs WeGuide a full replacement for Clario?
Honestly, no, and we're not going to pretend it is. For studies requiring cardiac safety, medical imaging, respiratory spirometry, or precision motion endpoints, Clario's specialised capabilities are genuinely irreplaceable and we'll tell you that upfront. WeGuide is the right choice when you need eCOA combined with patient engagement, eConsent, telehealth, registries, or wearables in a single platform, and when your protocol doesn't require specialised endpoint capture. If your study needs both, hybrid setups work well through our Integration Engine.
Does WeGuide offer provisioned devices like Clario?
No. WeGuide is BYOD-first and runs on participants' own phones, with whitelabel iOS and Android apps. For trials requiring validated provisioned devices at scale, especially for cardiac safety or respiratory endpoints where device control is part of the regulatory evidence chain, Clario remains the right choice. For general eCOA, BYOD is typically significantly cheaper and easier to scale, and it's what the teams we work with actively prefer.
How does WeGuide's eCOA compare to Clario's?
Clario's eCOA has deeper provisioned device logistics and 20 years of regulatory history behind it, which matters for enterprise pharma submissions. WeGuide's eCOA is integrated into the Form Builder with a library of 200+ validated instruments, runs inside a single participant facing whitelabel app alongside engagement content, eConsent, telehealth, and wearable data, and is designed for studies where the participant relationship matters as much as the endpoint capture. Different philosophies for different studies.
Does WeGuide do cardiac safety?
No. For ECG, Holter, 12 lead cardiac monitoring, and centralised cardiac safety reads, Clario or a specialist cardiac core lab is where you should be looking. This is one of the clearest cases where we recommend Clario over WeGuide, and we're comfortable saying so.
Can WeGuide integrate with Clario for endpoint data?
Yes. Our Integration Engine can pull Clario endpoint data into the WeGuide participant record, so sponsors running both platforms can keep Clario for specialised endpoint capture and use WeGuide for the participant experience, engagement, eConsent, and general eCOA work. We handle this integration as part of study configuration.
How does pricing compare?
Clario is enterprise custom quoted, typically at pharma scale budgets that reflect the full provisioned device logistics operation and specialised endpoint infrastructure. WeGuide is project based and scales to your study's actual complexity, with every module included in the core licence. For mid-market sponsors evaluating eCOA vendors, WeGuide is typically significantly more accessible. For pharma sponsors whose study genuinely needs Clario's specialised capabilities, Clario's pricing reflects what's actually in the product.
Compare WeGuide to other clinical trial platforms
Eleven more honest platform comparisons, from academic EDC to enterprise pharma.
.png){kind=small}
Veeva Vault Clinical
Life sciences cloud
Thread Research
Virtual CRO + software
Clario
eCOA specialist
Oracle Clinical
Clinical One & InForm
.png){kind=small}
OpenClinica
Open-source EDC
.png){kind=small}
Medable
DCT for top-50 pharma
.png){kind=small}
IQVIA
Full-service CRO
Florence Healthcare
Site-side workflow
Science 37
Open-source EDC
obviohealth
Virtual site service
Medidata Rave
Enterprise pharma stack
REDCap
Data Collection
Never miss an update
Get all the latest news, blog posts and product updates from WeGuide, delivered directly to your inbox. We'll rarely send more than one email a month.
By clicking Organise a demo, you're confirming that we can contact you to set up a demonstration.
Certified and Compliant by Leading Standards
